Evidence map›Paper›PMID 30899444›Full record

ArticleOncotarget2019

A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer.

Till Eichenauer, Mohammad Hussein, Claudia Hube-Magg, Martina Kluth, Franziska Büscheck, Doris Höflmayer, Maria Christina Tsourlakis, Stefan Steurer, Till S Clauditz, Andreas M Luebke and 13 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 1 country.

Till Eichenauer *Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Mohammad Hussein *Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Claudia Hube-MaggInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Martina KluthInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Franziska BüscheckInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Doris HöflmayerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Maria Christina TsourlakisInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Stefan SteurerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Till S ClauditzInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Andreas M LuebkeInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Eike BurandtInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Waldemar WilczakInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Andrea HinschInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
David DumInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Burkhard BeyerMartini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Thomas SteuberMartini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hartwig HulandMartini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Markus GraefenMartini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ronald SimonInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Guido SauterInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Nathaniel MellingDepartment of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Thorsten SchlommDepartment of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Sarah MinnerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
University Medical Center Hamburg-Eppendorf · DEUniversität Hamburg · DECharité - Universitätsmedizin Berlin · DEMartini-Klinik · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycogen synthase kinase 3ß (GSK3ß) regulates many cancer relevant cellular processes and represents a potential therapeutic target. GSK3ß overexpression has been linked to adverse tumor features in many cancers, but its role in prostate cancer remains uncertain. We employed immunohistochemical GSK3ß expression analysis on a tissue microarray with 12,427 prostate cancers. Cytoplasmic and nuclear GSK3ß staining was separately analyzed. GSK3ß staining was absent in normal prostate epithelium, whereas 57% of 9,164 interpretable cancers showed detectable GSK3ß expression. Cytoplasmic staining was considered weak, moderate, and strong in 36%, 19.5% and 1.5% of tumors and was accompanied by nuclear GSK3ß staining in 47% of cases. Cytoplasmic GSK3ß staining as well as nuclear GSK3ß accumulation was associated with advanced tumor stage, high Gleason grade, presence of lymph node metastasis and early biochemical recurrence (

Indexed as

GSK3betaimmunohistochemistryprognosisprostate cancer

Identifiers

PMID30899444
PMCPMC6422199
OpenAlexW2918697077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.